Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Breast Diseases 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × figitumumab × Clear all
NCT00372996 2015-10-28

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Pfizer

Phase 2 Terminated
219 enrolled 11 charts
Breast

Breast Neoplasms

NCT00678626 2015-05-04

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Pfizer

Phase 2 Withdrawn
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡